therapy), establishing the potential for using the information content of DNA to create multi-metalated radiopharmaceuticals. This programmable platform establishes a new paradigm for metalated molecular probe development with versatility for potential therapeutic, theranostic, and mass spectrometry-based applications, and potentially generalizable to other metal isotopes based on diagnostic or therapeutic requirements.
Wong et al. (Thu,) studied this question.